Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W)
Status:
Completed
Trial end date:
2020-06-30
Target enrollment:
Participant gender:
Summary
This phase II MATCH treatment trial identifies the effects of AZD4547 in patients whose
cancer has genetic changes called FGFR gene alterations. AZD4547 may stop the growth of
cancer cells by blocking FGFR proteins which may be needed for cell growth. Researchers hope
to learn if AZD4547 will shrink this type of cancer or stop its growth.